5% versus

2.7%, RR 2.0; 95% CI 0.25 to 16.37), agitation (4.6% versus 2.7%; RR 1.7; 95% CI 0.21 to 14.06), and headache (3.7% versus 0.0%; RR 3.1; 95% CI 0.17 to 56.41) met the ≥2% criteria. Day 8–36 AE rates were 41.0% (16 of 39) and 37.8% (14 of 37) with paliperidone palmitate and placebo respectively; anxiety (5.1% versus 0.0%; RR 4.8; 95% CI 0.24 to 95.76) met the ≥5% criteria. Key limitations were that some patients may have been ill for a significant time before formal diagnosis and that the number of patients is low in this subgroup, limiting the ability to detect Inhibitors,research,lifescience,medical statistical significance for AE RRs. Conclusions: Paliperidone palmitate initiation doses (150mgeq day1, see more 100mgeq day8) were tolerated in this subgroup of patients who were recently diagnosed with schizophrenia, with no unexpected findings. Although the same size was small, these data identified AEs that may be encountered during Inhibitors,research,lifescience,medical the week and month after initiation dosing. These findings may assist clinicians when paliperidone palmitate is considered an appropriate treatment choice for these patients. Keywords: paliperidone palmitate, recent diagnosis, schizophrenia, tolerability, treatment Introduction Population studies of schizophrenia have

Inhibitors,research,lifescience,medical shown occurrence rates ranging from 0.1 to 0.4 per 1000 persons per year [World Health Organization, 2007; Mueser and McGurk,

2004]. Schizophrenia is a disabling and progressive disease spanning the life course from premorbid, prodromal, to deterioration and chronic or residual stages. Of these four clinical stages of schizophrenia, the emergence of frank psychosis typically presents between Inhibitors,research,lifescience,medical the ages of 16 and 30years with the majority of patients in the ‘deterioration stage’ experiencing progressive functional decline with each successive relapse [Lieberman et al. 2008, 2001]. The deterioration experienced by those with schizophrenia Inhibitors,research,lifescience,medical appears to be most pronounced within the first 5years of disease onset [Tandon et al. 2009; Lieberman et al. 2001; McGlashan and Fenton, 1993; Bleuler, 1972]. Thus, it is generally accepted that the first 5–10years Astemizole of illness is a critical period for effective intervention [Francey et al. 2010; McGorry et al. 2008, 2007; Kelly et al. 2005; Marshall et al. 2005; Harrigan et al. 2003]. Several studies have found that earlier diagnosis and initiation of effective and well-tolerated treatment of schizophrenia is associated with greater clinical responsiveness and better long-term outcome, including a lower risk for recurrence [Weiden et al. 2009; Barnes et al. 2008; Perkins et al. 2005; Schooler et al. 2005; Wyatt, 1991], as well as possibly mitigating disease progression [Lieberman et al. 2001].